Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$216K Hold
450
0.01% 694
2025
Q4
$253K Hold
450
0.01% 649
2025
Q3
$231K Buy
+450
New +$196K 0.01% 693
2024
Q4
Sell
-750
Closed -$250K 794
2024
Q3
$250K Hold
750
0.01% 656
2024
Q2
$309K Hold
750
0.01% 538
2024
Q1
$303K Hold
750
0.01% 565
2023
Q4
$230K Sell
750
-400
-35% -$108K 0.01% 636
2023
Q3
$278K Hold
1,150
0.01% 559
2023
Q2
$276K Hold
1,150
0.01% 536
2023
Q1
$216K Buy
+1,150
New +$238K 0.01% 627
2019
Q1
Sell
-8,200
Closed -$434K 572
2018
Q4
$434K Sell
8,200
-3,500
-30% -$192K 0.03% 329
2018
Q3
$701K Buy
+11,700
New +$640K 0.04% 264

Other funds holding MEDP

Bailard's MEDP Position: Q1 2026 in Review

Bailard held its Medpace (MEDP) position steady in Q1 2026 at 450 shares worth $216K. The position accounts for 0.01% of the portfolio, ranked #694.

Bailard first reported a position in MEDP in Q3 2018 and has held it in 12 quarters since. The position peaked at $701K in Q3 2018. 729 funds tracked by Wall St. Rank hold MEDP as of Q1 2026.

  • Bailard held 450 shares of Medpace worth $216K as of Q1 2026.
  • Bailard left its Medpace share count unchanged in Q1 2026.
  • Medpace made up 0.01% of Bailard's portfolio in Q1 2026, its #694 holding.
  • Bailard first reported a position in Medpace in Q3 2018 and has held it in 12 quarters since.
  • Bailard's Medpace position peaked at $701K in Q3 2018.
  • 729 funds tracked by Wall St. Rank held Medpace as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.